Characteristics of patients and controls. Age, CRP and prednisolone dose are shown as mean (±SD)
| RA (N=53) | PsA/SpA (N=46) | HC (N=169) | |
| Age (years) | 56.15 (±11.80) | 51.33 (±12.92) | 46.18 (±12.56) |
| Female | 68% (n=36) | 48% (n=22) | 59% (n=100) |
| Male | 32% (n=17) | 52% (n=24) | 41% (n=69) |
| csDMARD | |||
| Methotrexate | 30 | 24 | None |
| Leflunomide | 3 | 2 | None |
| Azathioprine | 2 | None | |
| Hydroxycholorquine | 4 | None | |
| Salazopyrin | 2 | 2 | None |
| TNF inhibitor | |||
| Adalimumab | 4 | 13 | None |
| Certolizumab | 2 | None | |
| Etanercept | 2 | 3 | None |
| Golimumab | 6 | 5 | None |
| Infliximab | 2 | 2 | None |
| IL-17 inhibitor | |||
| Secukinumab | 5 | None | |
| Ixekizumab | 4 | None | |
| IL-6 inhibitor | |||
| Tocilizumab | 3 | None | |
| JAK inhibitor | |||
| Baricitinib | 3 | None | |
| Upadacitinib | 1 | 2 | None |
| Filgotinib | 1 | None | |
| Apremilast | 2 | None | |
| No therapy | 2 | 2 | 169 |
| Disease duration in years | 12.53 (±10.75) | 10.26 (±8.8) | |
| Treatment duration in months | 61.25 (±65.35) | 44.79 (±49.8) | |
| Disease activity | |||
|
SJ count (28) SJ=0: 63% SJ ≥1: 37% | 1.24 (±2.34) | 0.64 (±1.23) | |
| TJ count (28) | 2.71 (±3.55) | 4.15 (±8.59) | |
| CRP | 0.35 mg/dL (±0.63) | 0.30 mg/dL (±0.38) | |
| Seropositive | N=24 | ||
| Prednisolone dose | |||
| Patients without prednisolone | N=39 | N=38 | N=169 |
| Patients with daily prednisolone at 1. vaccination | N=7 Mean dose: 5.53 mg/day (±4.19) | N=3 Mean dose: 8.33 mg/day (±3.82) | None |
| Patients without prednisolone | N=38 | N=38 | N=169 |
| Patients with daily prednisolone at 2. vaccination | 7.31 mg/day (±7.73) N=8 | 8.33 mg/day (±3.81) N=3 | None |
CRP, C-reactive protein; csDMARD, conventional synthetic DMARD; HC, healthy controls; IL, interleukin; JAK, Janus kinase; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SJ, swollen joint; SpA, seronegative spondyloarthritis; TJ, tender joint; TNF, tumour necrosis factor.